These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Rojo LE; Gaspar PA; Silva H; Risco L; Arena P; Cubillos-Robles K; Jara B Pharmacol Res; 2015 Nov; 101():74-85. PubMed ID: 26218604 [TBL] [Abstract][Full Text] [Related]
5. A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics. Jesus C; Jesus I; Agius M Psychiatr Danub; 2015 Sep; 27 Suppl 1():S489-91. PubMed ID: 26417824 [TBL] [Abstract][Full Text] [Related]
6. Schizophrenia. Holder SD; Wayhs A Am Fam Physician; 2014 Dec; 90(11):775-82. PubMed ID: 25611712 [TBL] [Abstract][Full Text] [Related]
7. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic. Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186 [TBL] [Abstract][Full Text] [Related]
8. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Siafis S; Tzachanis D; Samara M; Papazisis G Curr Neuropharmacol; 2018; 16(8):1210-1223. PubMed ID: 28676017 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Adipose Tissue Transcriptome Highlights Specific Expression Profiles in Severe Pediatric Obesity: A Pilot Study. Berardo C; Calcaterra V; Mauri A; Carelli S; Messa L; Destro F; Rey F; Cordaro E; Pelizzo G; Zuccotti G; Cereda C Cells; 2023 Apr; 12(8):. PubMed ID: 37190014 [TBL] [Abstract][Full Text] [Related]
11. Mechanism and treatments of antipsychotic-induced weight gain. Ye W; Xing J; Yu Z; Hu X; Zhao Y Int J Obes (Lond); 2023 Jun; 47(6):423-433. PubMed ID: 36959286 [TBL] [Abstract][Full Text] [Related]
12. The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications. Chen H; Cao T; Zhang B; Cai H Front Pharmacol; 2023; 14():1097284. PubMed ID: 36762113 [TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-induced weight gain and metabolic effects show diurnal dependence and are reversible with time restricted feeding. Zapata RC; Silver A; Yoon D; Chaudry B; Libster A; McCarthy MJ; Osborn O Schizophrenia (Heidelb); 2022 Aug; 8(1):70. PubMed ID: 36042214 [TBL] [Abstract][Full Text] [Related]
14. The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study. Hakami AY; Felemban R; Ahmad RG; Al-Samadani AH; Salamatullah HK; Baljoon JM; Alghamdi LJ; Ramadani Sindi MH; Ahmed ME Front Psychiatry; 2022; 13():914165. PubMed ID: 35686187 [TBL] [Abstract][Full Text] [Related]
15. Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. Singh R; Stogios N; Smith E; Lee J; Maksyutynsk K; Au E; Wright DC; De Palma G; Graff-Guerrero A; Gerretsen P; Müller DJ; Remington G; Hahn M; Agarwal SM Ther Adv Psychopharmacol; 2022; 12():20451253221096525. PubMed ID: 35600753 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview. Borovcanin MM; Vesic K; Jovanovic M; Mijailovic NR World J Diabetes; 2021 Oct; 12(10):1731-1739. PubMed ID: 34754374 [TBL] [Abstract][Full Text] [Related]
17. Adiponectin Is Related to Cardiovascular Risk in Severe Mental Illness Independent of Antipsychotic Treatment. Reponen EJ; Tesli M; Dieset I; Steen NE; Vedal TSJ; Szabo A; Werner MCF; Lunding SH; Johansen IT; Rødevand LN; Andreassen OA; Ueland T Front Psychiatry; 2021; 12():623192. PubMed ID: 34122163 [No Abstract] [Full Text] [Related]
18. Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Carli M; Kolachalam S; Longoni B; Pintaudi A; Baldini M; Aringhieri S; Fasciani I; Annibale P; Maggio R; Scarselli M Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33800403 [TBL] [Abstract][Full Text] [Related]
19. Secondary dyslipidemia: its treatments and association with atherosclerosis. Yanai H; Yoshida H Glob Health Med; 2021 Feb; 3(1):15-23. PubMed ID: 33688591 [TBL] [Abstract][Full Text] [Related]